CD19 and B-cell non-Hodgkin lymphoma: We first investigated whether CAR T cell therapy based on 2nd Gen CARs specific for CD19 (Tisagenleceucel, Novartis), CD20 (Miltenyi), and bispecific for CD20 and CD19 (Miltenyi) has an impact on CD80/86 expression on B cell lymphoma tissue.